Cargando…

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib

BACKGROUND: The existence of a cross-talk between peritumoral adipocytes and cancer cells has been increasingly investigated. Several studies have shown that these adipocytes protect tumor cells from the effect of anticancer agents. METHODS: To investigate a potential protective effect of adipocyte-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geneste, A., Duong, M. N., Molina, L., Conilh, L., Beaumel, S., Cleret, A., Chettab, K., Lachat, M., Jordheim, L. P., Matera, E. L., Dumontet, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427918/ https://www.ncbi.nlm.nih.gov/pubmed/32795383 http://dx.doi.org/10.1186/s40360-020-00436-z

Ejemplares similares

Characterization of T‐DM1‐resistant breast cancer cells
por: Sauveur, Juliette, et al.
Publicado: (2020)

Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
por: Duong, Minh Ngoc, et al.
Publicado: (2015)

The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance
por: Duong, Minh Ngoc, et al.
Publicado: (2017)

Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding
por: Hirz, Taghreed, et al.
Publicado: (2017)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
por: Chettab, Kamel, et al.
Publicado: (2023)

Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway
por: Sauveur, Juliette, et al.
Publicado: (2018)

Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
por: Conilh, Louise, et al.
Publicado: (2021)

Payload diversification: a key step in the development of antibody–drug conjugates
por: Conilh, Louise, et al.
Publicado: (2023)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Transcriptional and Metabolic Investigation in 5′-Nucleotidase Deficient Cancer Cell Lines
por: Cadassou, Octavia, et al.
Publicado: (2021)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP)
por: Lehuédé, Camille, et al.
Publicado: (2019)

Human Adipocyte Conditioned Medium Promotes In Vitro Fibroblast Conversion to Myofibroblasts
por: El-Hattab, Mariam Y., et al.
Publicado: (2020)

Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin
por: Delort, Laetitia, et al.
Publicado: (2019)

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
por: Deblois, Geneviève, et al.
Publicado: (2016)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
por: Farrugia, M K, et al.
Publicado: (2015)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
por: Bao, Shengnan, et al.
Publicado: (2020)

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene
por: Galmarini, Carlos María, et al.
Publicado: (2004)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Successful fat-only whole breast reconstruction using cultured mature adipocytes and conditioned medium containing MCP-1
por: Yanaga, Hiroko, et al.
Publicado: (2023)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer()()
por: Zhang, Lixin, et al.
Publicado: (2015)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005)

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
por: Grasselly, Chloé, et al.
Publicado: (2018)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
por: Wang, Jun, et al.
Publicado: (2020)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer
por: Nelson, Michael H, et al.
Publicado: (2007)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells
por: Ma, S, et al.
Publicado: (2016)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
por: Yallowitz, Alisha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k1qi2cc8fmek3k78uppu8pifdu